Date: 2015-02-27
Type of information: Private placement
Company: Celyad previously known as Cardio3 Biosciences (Belgium)
Investors:
Amount: € 32 million
Funding type: private placement
Planned used: The proceeds from the private placement will be used to further develop Cardio3 BioSciences\' newly acquired CAR-T cell technology platform and to strengthen the leadership of C-Cure® for the treatment of congestive heart failure. The funds will also be used for general corporate purposes.
Others: * On February 27, 2015, Cardio3 BioSciences announced it has raised approximately €32 million through a private placement of ordinary shares to investors in the United States and Europe. Cardio3 BioSciences has placed 713,380 new shares to qualified institutional investors in the United States and Europe at a price of €44.50 per share, with no discount to the previous day closing price and a 4% premium to the last 30 day average price. The placed shares represent 10% of the current number of outstanding shares, bringing the total number of shares outstanding after the issue to 7,847,187. The new shares are expected to be admitted to trading on Euronext Brussels and Paris following their issuance, which is expected to take place on Tuesday, 3 March 2015. This placement was successfully led by UBS Investment Bank, acting as Global Coordinator and Bookrunner for the offering, and Petercam and Bryan Garnier & Co as Placement Agents.
Therapeutic area: Cardiovascular diseases - Cancer - Oncology
